Medovate and JEB Technologies are to become one company – combining their teams, operations and expertise under the Medovate name.

The combined expertise across both companies will become part of an expanded offering spanning medical device design, development, manufacturing, regulatory approval, international launch and commercialisation.

The move follows two years of close collaboration between the businesses, during which their products have launched in more than 12 international markets, including the USA, Australia, New Zealand, the United Arab Emirates, Saudi Arabia and several European countries.

Its current portfolio includes SAFIRA, a system designed to help improve safety during regional anaesthesia; and CamPROBE, a simple and cost-effective solution that is intended to facilitate transperineal prostate biopsies under local anaesthetic. Products currently in development include LumeVac and TransiCap.

Medovate plans to secure regulatory approval for a new medical device and launch it in the USA and Europe during 2027. Further products are expected to progress towards regulatory approval and international launch in 2028.